Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results